Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Free Cash Flow (2016 - 2025)

Ironwood Pharmaceuticals' Free Cash Flow history spans 16 years, with the latest figure at $74.6 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 390.18% year-over-year to $74.6 million; the TTM value through Dec 2025 reached $127.0 million, up 22.83%, while the annual FY2025 figure was $127.0 million, 22.83% up from the prior year.
  • Free Cash Flow for Q4 2025 was $74.6 million at Ironwood Pharmaceuticals, up from $47.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $80.2 million in Q1 2023 and bottomed at -$15.1 million in Q2 2025.
  • The 5-year median for Free Cash Flow is $48.1 million (2021), against an average of $47.4 million.
  • The largest YoY upside for Free Cash Flow was 390.18% in 2025 against a maximum downside of 145.11% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $64.4 million in 2021, then grew by 22.92% to $79.2 million in 2022, then plummeted by 55.03% to $35.6 million in 2023, then tumbled by 57.29% to $15.2 million in 2024, then skyrocketed by 390.18% to $74.6 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Free Cash Flow are $74.6 million (Q4 2025), $47.6 million (Q3 2025), and -$15.1 million (Q2 2025).